DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCorporate Action

Bliss GVS Pharma Limited — Cessation

NSE 1 hr ago·24 Jul 2026, 2:21 pm

Bliss GVS Pharma

Bliss GVS Pharma has announced that Mr. Sachin Saboo has ceased to serve as a Director of the company with effect from July 24, 2026. This information was submitted to the stock exchanges to ensure transparency regarding changes in the company's leadership structure. The company has stated that this is a routine administrative update and does not reflect any internal issues or operational changes.

For investors, this news is largely a procedural update rather than a market-moving event. While leadership changes can sometimes influence a company's strategy, the company has indicated that this is a standard administrative shift. Investors should focus on the company's future business performance and operational metrics rather than this specific personnel change.